12:00 AM
 | 
Mar 12, 2012
 |  BC Week In Review  |  Company News  |  Deals

Lipid Therapeutics, Dr. Falk Pharma deal

Dr. Falk exercised an option to license European rights to ulcerative colitis (UC) product LT-02 from Lipid Therapeutics. Lipid Therapeutics will receive an undisclosed upfront payment and will be eligible for milestones and royalties....

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >